πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,022 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11958850

Heteroaryl compounds for kinase inhibition

Takeda Pharmaceutical Company Limited Β· Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11957867

Syringe stabilizer

Takeda Pharmaceutical Company Limited Β· Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11958845

Heterocyclic compound

Takeda Pharmaceutical Company Limited Β· Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11957684

Treatment of heavy menstrual bleeding associated with uterine fibroids

Takeda Pharmaceutical Company Limited Β· Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11952344

Heterocyclic compound and use thereof

Takeda Pharmaceutical Company Limited Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11938174

Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorde

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11939327

Heterocyclic compounds

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11905285

Inhibitors of plasma kallikrein and uses thereof

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11897879

Heterocyclic compound

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11892450

Evaluation, assays and treatment of pKal-mediated disorders

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11884945

Methods for purification of arylsulfatase A

Takeda Pharmaceutical Company Limited Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11884731

Vedolizumab for the treatment of fistulizing Crohn's disease

Takeda Pharmaceutical Company Limited Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11857575

Mesenchymal stem cell-derived exosomes and their uses

Takeda Pharmaceutical Company Limited Β· Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11851449

Heterocyclic amide compounds having an RORvt inhibitory action

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11851481

Treatment of central nervous system disorders by intranasal administration of immunoglobul

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11834409

Heterocyclic NMDA antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11827601

Heterocyclic NMDA antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11815516

Protein biomarkers for diseases associated with the contact activation system

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11793855

TFPI inhibitors and methods of use

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11795216

Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as anal

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11793812

Methods of treating endometriosis

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11787796

Plasma Kallikrein inhibitors and uses thereof

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11786608

Isoquinolinyl triazolone complexes

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11780904

Method of producing recombinant high molecular weight vWF in cell culture

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted